Journal Information
Full text access
Does therapy with spironolactone increase the effect of ACEIs and ARA-II for managing proteinuria and renal failure progression in patients with chronic renal disease?
¿El tratamiento con espironolactona incrementa el efecto de IECAS y ARAII en el control de la proteinuria y la progresión de la insuficiencia renal en pacientes con ERC?
Visits
3055
A. Ramos, C. Caramelo
This item has received
Article information